WSJ : Oaktree Raises About $3 Billion for Latest Special-Situations Fund

Oaktree Raises About $3 Billion for Latest Special-Situations Fund
The distressed-investing giant’s new fund makes private-equity and debt investments in midmarket businesses

Oaktree Capital Management has closed its third special-situations fund to invest in midmarket companies struggling with high debt or other financial challenges.

Oaktree wrapped up fundraising for its Special Situations Fund III with about $3 billion, including commitments to related vehicles, people familiar with the matter said. The sum exceeds the Los Angeles firm’s initial target of $2.5 billion and the $2.3 billion raised by a 2018-vintage predecessor fund, the people said.

Investors that committed to the new pool as limited partners include the Minnesota State Board of Investments and the Teachers’ Retirement System of Louisiana, according to public pension-fund documents.

Oaktree amassed the sum during a difficult time for raising capital for private-equity and private-debt vehicles aimed at backing companies under financial stress. Such funds surged in popularity in 2020 and early 2021, as the Covid pandemic spurred high rates of corporate defaults and created an abundance of investment opportunities, but they have since struggled to gain traction among investors.

Funds that invest in distressed debt raised just under $10 billion globally from the start of the year through Oct. 27, down from about $32 billion in 2022 and $37 billion in 2021, according to PitchBook Data, which collects information about private markets.

Oaktree’s fundraising effort may have been boosted by a strong performance so far by the credit specialist’s previous special-situations fund. It posted an internal rate of return of about 45% through June, according to data from the School Employees Retirement System of Ohio, which backed the vehicle.

Oaktree manages about $183 billion across debt, private equity, real assets and other strategies. Founded in 1995, Oaktree went public in 2012, and was taken private again in 2019 by Canadian asset-management firm Brookfield.

Oaktree’s special-situations funds are more like private-equity funds than distressed-debt vehicles, though they invest in both debt and equity. The funds are intended to thrive in good and bad financial conditions, targeting private equity-like returns by backing companies contending with temporary financial issues.

Oaktree’s special-situations funds typically invest around $125 million to $150 million per deal in North American midmarket companies broadly across industries and sectors. The funds aim for control or significant influence over the businesses they back. So far, the firm has invested about $1 billion from its new vehicle.

Companies backed by Oaktree’s special-situations strategy include MBS Group, which provides services to film and television studios, and barbecue grill maker Blackstone Products.

>>> Pfizer reaffirms FY23 guidance, sees FY24 EPS and revenue below consensus in

Pfizer reaffirms FY23 guidance, sees FY24 EPS and revenue below consensus including expected contribution from Seagen acquisition (28.58)
  • Co reaffirms guidance for FY23 (Dec), sees EPS of $1.45-1.65 vs. $1.73 FactSet Consensus; sees FY23 (Dec) revs of $58-61 bln vs. $59.65 bln FactSet Consensus.
  • Co issues downside guidance for FY24 (Dec), sees EPS of $2.05-2.25 vs. $3.17 FactSet Consensus; sees FY24 (Dec) revs of $58.5-61.5 bln vs. $62.66 bln FactSet Consensus.
  • Pfizer expects full-year 2024 revenues to be in the range of $58.5 to $61.5 billion, which includes approximately $8 billion in anticipated revenues for Comirnaty and Paxlovid, approximately $3.1 billion in anticipated revenues from Seagen and approximately $1 billion related to the reclassification of Pfizer's royalty income from Other (Income)/Deductions into the Revenue line. Including the contribution from Seagen and excluding revenues from Comirnaty(2) and Paxlovid, Pfizer expects to achieve full-year 2024 operational(3) revenue growth of 8% to 10%. Excluding revenues from Comirnaty(2) and Paxlovid and the expected contribution from Seagen, Pfizer expects to achieve full-year 2024 operational(3) revenue growth of 3% to 5%. Both expected operational(3) growth rate ranges are compared with the mid-point of Pfizer's full-year 2023 revenue guidance range provided on October 31, 2023, and account for the reclassification of royalty income. While the company will begin reporting royalty income in the revenue line in 2024, for growth rate purposes, the company has included royalty income in both 2023 and 2024. Consequently, there is no operational revenue growth attributable to the reclassification of royalty income.
  • Dr. Albert Bourla, Pfizer Chairman and Chief Executive Officer, stated: "Pfizer's product portfolio remains strong. In 2024, Comirnaty and Paxlovid are expected to deliver combined revenues of approximately $8 billion and our remaining portfolio of combined Pfizer and Seagen products is expected to achieve year-over-year operational revenue growth in the range of 8% to 10%. "In addition, we expect our cost realignment program to deliver savings of at least $4.0 billion by the end of 2024, which puts us on a path to potentially regain our pre-pandemic operating margins."

>>> US Early premarket gappers

Early premarket gappers
  • Gapping up:
    • CCCC +7.5%, BBAI +6.6%, LFMD +6.4%, SLM +3.8%, TTWO +3.4%, CRBU +2.8%, COMP +2.6%, HCM +2.6%, TTC +2.4%, VERX +2.3%, VET +1.4%, HBNC +1.3%, PLAB +1.3%, ABNB +1.1%, VRTX +1.1%, CVLY +0.8%, UGI +0.7%
  • Gapping down:
    • SOS -3.3%, XPEV -2.8%, SHEL -0.6%, WBD -0.5%

>>> Europe : Brokers Upgrades & Downgrades - 13th of December 2023 V3(++)

>>> Up
* Arkema Raised to Buy at UBS (++)
* Atlantic Sapphire ASA Raised to Hold at SpareBank
* BASF Raised to Buy at UBS (++)
* CGG Raised to Outperform at Oddo BHF; PT 90 euro cents
* Continental Raised to Buy at BofA; PT 89 euros (++)
* Paragon Raised to Outperform at RBC; PT 850 pence
* Porsche AG Raised to Buy at HSBC; PT 100 euros
* TotalEnergies Raised to Outperform at BNPP Exane; PT 75 euros
* VW Raised to Neutral at BNPP Exane
* Wavestone Raised to Buy at IDMidcaps; PT 55 euros (+)
* Wolters Kluwer Raised to Overweight at JPMorgan; PT 145 euros

>>> Down
* Adevinta Cut to Equal-Weight at Barclays; PT 115 kroner
* Anglo American Cut to Hold at HSBC; PT 1,800 pence
* Aixtron Cut to Hold at M.M. Warburg; PT 36.50 euros (+)
* Ferrari Cut to Hold at HSBC
* Ferrari Cut to Neutral at BNPP Exane
* Ford Cut to Neutral at BNPP Exane
* Hemnet Cut to Hold at Pareto Securities; PT 230 kronor
* Inditex Cut to Sell at Alantra Equities; PT 39.50 euros (+)
* LVMH Cut to Neutral at JPMorgan; PT 790 euros
* Mercedes Cut to Underperform at BNPP Exane
* Repsol Cut to Neutral at BNPP Exane; PT 15 euros
* S&U Cut to Add at Peel Hunt; PT 2,500 pence (++)
* Shell Cut to Neutral at BNPP Exane
* Viaplay Cut to Sell at DNB Markets; PT 5.30 kronor (+)
* WPP Cut to Neutral at JPMorgan; PT 850 pence

>>> Initiation
* Avolta AG Rated New Hold at Research Partners (++)
* Better Collective Rated New Buy at Jefferies; PT 340 kronor
* Cibus Nordic Real Estate Rated New Sell at ABG; PT 125 kronor (+)
* Exclusive Networks Rated New Underperform at Oddo BHF
* Gigante Salmon Rated New Buy at SpareBank; PT 16 kroner
* Grifols Rated New Buy at SocGen
* Metso Cut to Underperform at BofA (++)
* Sagax Rated New Buy at ABG; PT 290 kronor (++)
* Siegfried Rated New Buy at SocGen; PT 966 Swiss francs
* Syensqo Rated New Buy at Deutsche Bank; PT 115 euros
* VAT Rated New Buy at William O'Neil (+)
* Visteon Cut to Neutral at BNPP Exane; PT $130 (+)
* Weir Cut to Underperform at BofA (++)

>>> Call
* BASF, Arkema Rise as UBS Upgrades to Buy on 2024 Volume Recovery (++)
* Better Collective Rises; Jefferies Rates New Buy on Growth Path (++)
* Goldman, Citi Bet Rate Cuts Will Fuel Equity Rally: Taking Stock (+)
* JPMorgan Sees a Regional Bank Stock Rally as Investor Angst Ebbs
* Inditex Update Points to More Consensus Upgrades: Jefferies (+)
* Porsche Raised to Buy at HSBC as Pricing Worries Appear Overdone (+)
* Storebrand Drops as Jefferies Says New Goals Below Consensus (++)
* Weir Group Drops on Double Downgrade to Underperform From BofA (++)

WWD : Adidas Responds to Thom Browne’s ‘Unclean Hands’ Argument

Adidas Responds to Thom Browne’s ‘Unclean Hands’ Argument
The sports brand is seeking a new trial over the designer's use of stripes due to some newly discovered emails.


It’s not important how Adidas discovered the “smoking gun” emails it unearthed regarding Thom Browne’s use of stripes. But the fact that they exist at all warrants a new trial.

That was the response of the attorneys for Adidas in its ongoing battle with the designer over the use of stripes in his athletic-inspired offering.

As reported, Judge Jed Rakoff of the Southern District of New York has scheduled a hearing between the two parties on Dec. 21 to hear arguments devoted to intent in the discovery of several emails that surfaced following a jury decision earlier this year.

Adidas sued Browne for using four stripes on some of the American designer’s active-inspired merchandise, saying it created confusion with the sports brand. The designer had been using stripes on his collections for many years to reference collegiate varsity sweaters, but, after being approached by Adidas in 2007, agreed to change the design to four parallel bars. Adidas has been using its three-stripe bar in the U.S. since the 1950s and spends $300 million a year in advertising the stripes, and products sporting the mark account for $3.1 billion in annual sales.


In January, an eight-person jury in Manhattan’s Southern District came back with a verdict that found Browne was not liable for damages or profits that it made selling products with four stripes or its trademark grosgrain ribbon.

Adidas in October discovered four emails that it characterized as “bad faith” from employees who cautioned the designer about using specific stripe designs in its collections because they could potentially create confusion with Adidas. The emails surfaced in August during a separate trademark dispute between the two companies in the U.K. but were not disclosed during the initial trial.

Browne’s legal team on Friday said “Adidas’ hands are not clean” — alleging the sports brand breached a U.K. confidentiality agreement by sharing the emails with the company’s U.S. counsel much earlier than it had originally disclosed.

In response, Adidas’s attorney wrote: “For Thom Browne, there is no escaping the fact that it withheld smoking-gun evidence and got caught.” The company’s argument about when Adidas found the emails is irrelevant, it claimed. “Thom Browne asks the court to ignore its own egregious misconduct and focus instead on how that egregious misconduct was brought to light. The court should deny that unjust request and reject Thom Browne’s meritless ‘unclean hands’ argument.”

The filing went on to say that while Adidas’ attorney admitted the company had seen the emails earlier than it originally acknowledged, that breach was “inadvertent and harmless,” opening the door for a new trial.

>>> Europe : Brokers Upgrades & Downgrades - 13th of December 2023 V2(+)

>>> Up
* Atlantic Sapphire ASA Raised to Hold at SpareBank
* CGG Raised to Outperform at Oddo BHF; PT 90 euro cents
* Paragon Raised to Outperform at RBC; PT 850 pence
* Porsche AG Raised to Buy at HSBC; PT 100 euros
* TotalEnergies Raised to Outperform at BNPP Exane; PT 75 euros
* VW Raised to Neutral at BNPP Exane
* Wavestone Raised to Buy at IDMidcaps; PT 55 euros (+)
* Wolters Kluwer Raised to Overweight at JPMorgan; PT 145 euros

>>> Down
* Adevinta Cut to Equal-Weight at Barclays; PT 115 kroner
* Anglo American Cut to Hold at HSBC; PT 1,800 pence
* Aixtron Cut to Hold at M.M. Warburg; PT 36.50 euros (+)
* Ferrari Cut to Hold at HSBC
* Ferrari Cut to Neutral at BNPP Exane
* Ford Cut to Neutral at BNPP Exane
* Hemnet Cut to Hold at Pareto Securities; PT 230 kronor
* Inditex Cut to Sell at Alantra Equities; PT 39.50 euros (+)
* LVMH Cut to Neutral at JPMorgan; PT 790 euros
* Mercedes Cut to Underperform at BNPP Exane
* Repsol Cut to Neutral at BNPP Exane; PT 15 euros
* Shell Cut to Neutral at BNPP Exane
* Viaplay Cut to Sell at DNB Markets; PT 5.30 kronor (+)
* WPP Cut to Neutral at JPMorgan; PT 850 pence

>>> Initiation
* Better Collective Rated New Buy at Jefferies; PT 340 kronor
* Cibus Nordic Real Estate Rated New Sell at ABG; PT 125 kronor (+)
* Exclusive Networks Rated New Underperform at Oddo BHF
* Gigante Salmon Rated New Buy at SpareBank; PT 16 kroner
* Grifols Rated New Buy at SocGen
* Siegfried Rated New Buy at SocGen; PT 966 Swiss francs
* Syensqo Rated New Buy at Deutsche Bank; PT 115 euros
* VAT Rated New Buy at William O'Neil (+)
* Visteon Cut to Neutral at BNPP Exane; PT $130 (+)

>>> Call
* Goldman, Citi Bet Rate Cuts Will Fuel Equity Rally: Taking Stock (+)
* JPMorgan Sees a Regional Bank Stock Rally as Investor Angst Ebbs
* Inditex Update Points to More Consensus Upgrades: Jefferies (+)
* Porsche Raised to Buy at HSBC as Pricing Worries Appear Overdone (+)

FT : UK economy shrinks unexpectedly in October

UK economy shrinks unexpectedly in October
Economy weaker than forecast as every sector declines

The UK economy unexpectedly contracted in October, driven by falls in every sector and fuelling concerns that high interest rates could push the country into a downturn.

Gross domestic product fell 0.3 per cent between September and October, data published by the Office for National Statistics showed on Wednesday.

Economists had expected no change in GDP after a 0.2 per cent expansion the previous month.

Services output fell by 0.2 per cent in October, driven by a fall in information and communication, and was the main contributor to the decline in GDP.

Production and construction also fell sharply, by 0.8 per cent and 0.5 per cent, respectively.

The data comes ahead of Thursday’s Bank of England decision on monetary policy. The central bank is expected to keep interest rates unchanged at a 15-year high of 5.25 per cent.